Omnicell (NASDAQ:OMCL) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Omnicell (NASDAQ:OMCL) from a hold rating to a buy rating in a research report released on Wednesday.

Several other analysts have also recently issued reports on OMCL. Bank of America upped their target price on Omnicell from $34.00 to $44.00 and gave the company a buy rating in a report on Friday, August 2nd. Benchmark restated a buy rating and set a $38.00 price objective on shares of Omnicell in a research report on Monday, July 15th. Wells Fargo & Company boosted their target price on shares of Omnicell from $26.00 to $30.00 and gave the company an equal weight rating in a report on Friday, August 2nd. JPMorgan Chase & Co. raised their price target on shares of Omnicell from $26.00 to $37.00 and gave the stock a neutral rating in a report on Friday, August 23rd. Finally, Barclays raised shares of Omnicell from an underweight rating to an equal weight rating and lifted their price target for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Omnicell has a consensus rating of Moderate Buy and a consensus price target of $37.83.

Omnicell Stock Up 0.8 %

NASDAQ OMCL opened at $43.16 on Wednesday. Omnicell has a one year low of $25.12 and a one year high of $56.06. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The business has a fifty day moving average price of $37.42 and a 200 day moving average price of $31.66. The company has a market cap of $1.98 billion, a P/E ratio of -93.83, a P/E/G ratio of 47.48 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The business had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company’s quarterly revenue was down 7.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 earnings per share. Research analysts anticipate that Omnicell will post 0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently added to or reduced their stakes in the business. Algert Global LLC boosted its position in Omnicell by 9.8% during the second quarter. Algert Global LLC now owns 51,942 shares of the company’s stock worth $1,406,000 after purchasing an additional 4,617 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Omnicell by 6.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,459 shares of the company’s stock worth $635,000 after acquiring an additional 1,360 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its stake in Omnicell by 238.4% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 31,474 shares of the company’s stock valued at $852,000 after buying an additional 22,174 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Omnicell by 10.3% in the second quarter. AQR Capital Management LLC now owns 49,071 shares of the company’s stock valued at $1,328,000 after acquiring an additional 4,572 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Omnicell during the 2nd quarter worth about $1,623,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.